Apoptotic effects of a progesterone receptor antagonist on rat granulosa cells are not mediated via reduced protein isoprenylation

2007 ◽  
Vol 74 (10) ◽  
pp. 1317-1326 ◽  
Author(s):  
P. Anders Friberg ◽  
D.G. Joakim Larsson ◽  
Emilia Rung ◽  
Håkan Billig
2010 ◽  
Vol 315 (1-2) ◽  
pp. 121-130 ◽  
Author(s):  
P. Anders Friberg ◽  
D.G. Joakim Larsson ◽  
Håkan Billig

ChemInform ◽  
2010 ◽  
Vol 29 (51) ◽  
pp. no-no
Author(s):  
C. L. F. POOLEY ◽  
J. P. EDWARDS ◽  
M. E. GOLDMAN ◽  
M.-W. WANG ◽  
K. B. MARSCHKE ◽  
...  

2019 ◽  
Vol 39 (7) ◽  
Author(s):  
Lindong Zhang ◽  
Quanling Feng ◽  
Zhiting Wang ◽  
Pingping Liu ◽  
Shihong Cui

Abstract Uterine leiomyoma is the most common benign smooth muscle tumor of uterus in women of reproductive age, with a high lifetime incidence. Nowadays, the exploration on the pharmacotherapies, such as progesterone receptor antagonist (PRA) requires more attention. Hence, the current study aimed to examine whether mifepristone, a PRA, influences the autophagy and apoptosis of uterine leiomyoma cells. Primary uterine leiomyoma cells were collected from 36 patients diagnosed with uterine leiomyoma to establish PR-M-positive (PR-M[+]) cells. The lentiviral vector overexpressing or silencing PR-M was subsequently delivered into one part of PR-M(+) cells in order to evaluate the role of PR-M in PR-M(+) cells. The results obtained revealed that cell viability was increased, while cell autophagy and apoptosis were diminished in the PR-M(+) cells treated with overexpressed PR-M, whereby the Bcl-2 level was elevated and the level of Beclin1 was reduced. An opposite trends were identified following treatment with knockdown of PR-M. Mifepristone at different concentrations (low, moderate, or high) was then applied to treat another part of the PR-M(+) cells. Mifepristone was identified to promote cell autophagy and apoptosis, decrease Bcl-2 level and increase Beclin1 level, accompanied by weakened interaction between Bcl-2 and Beclin1. Moreover, these effects of mifepristone on PR-M(+) cells were enhanced with increasing of the concentration. Taken together, the present study present evidence indicates the ability of PRA to regulate the Bcl-2/Beclin1 axis, ultimately promoting the autophagy and apoptosis of uterine leiomyoma cells, highlighting that PRA serves as a promising therapeutic target for the treatment of uterine leiomyoma.


1999 ◽  
Vol 35 (2) ◽  
pp. 214-218 ◽  
Author(s):  
J.F.R Robertson ◽  
P.C Willsher ◽  
L Winterbottom ◽  
R.W Blamey ◽  
S Thorpe

2010 ◽  
Vol 136 (10) ◽  
pp. 1461-1469 ◽  
Author(s):  
Ramin Ataee ◽  
Soheila Ajdary ◽  
Mohammadreza Zarrindast ◽  
Mehdi Rezayat ◽  
Mohammad Reza Hayatbakhsh

2011 ◽  
Vol 14 (1) ◽  
pp. 149-158 ◽  
Author(s):  
R. Rękawiecki ◽  
M. Kowalik ◽  
J. Kotwica

Nuclear progesterone receptor isoforms and their functions in the female reproductive tract Progesterone (P4), which is produced by the corpus luteum (CL), creates proper conditions for the embryo implantation, its development, and ensures proper conditions for the duration of pregnancy. Besides the non-genomic activity of P4 on target cells, its main physiological effect is caused through genomic action by the progesterone nuclear receptor (PGR). This nuclear progesterone receptor occurs in two specific isoforms, PGRA and PGRB. PGRA isoform acts as an inhibitor of transcriptional action of PGRB. The inactive receptor is connected with chaperone proteins and attachment of P4 causes disconnection of chaperones and unveiling of DNA binding domain (DBD). After receptor dimerization in the cells' nucleus and interaction with hormone response element (HRE), the receptor coactivators are connected and transcription is initiated. The ratio of these isoforms changes during the estrous cycle and reflects the different levels of P4 effect on the reproductive system. Both isoforms, PGRA and PGRB, also show a different response to the P4 receptor antagonist activity. Connection of the antagonist to PGRA can block PGRB, but acting through the PGRB isoform, P4 receptor antagonist may undergo conversion to a strongly receptor agonist. A third isoform, PGRC, has also been revealed. This isoform is the shortest and does not have transcriptional activity. Alternative splicing and insertion of additional exons may lead to the formation of different PGR isoforms. This paper summarizes the available data on the progesterone receptor isoforms and its regulatory action within the female reproductive system.


2004 ◽  
Vol 15 (2) ◽  
pp. 359-365 ◽  
Author(s):  
Claudia Hödl ◽  
Wolfgang S. L. Strauss ◽  
Reinhard Sailer ◽  
Christoph Seger ◽  
Rudolf Steiner ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document